SELLAS Life Sciences Announces Recommendation Of Independent Data Monitoring Committee Following Completion Of Enrollment In REGAL Phase 3 Study
SELLAS Life Sciences Announces Recommendation Of Independent Data Monitoring Committee Following Completion Of Enrollment In REGAL Phase 3 Study
在完成REGAL三期研究的注册后，SELLAS生命科学宣布了独立数据监测委员会的建议
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications –
— 根据评估的疗效和安全性数据，独立数据监测委员会（IDMC）建议在不进行任何修改的情况下继续进行3期REGAL试验患者治疗和随访—
– IDMC Will Convene Again Ahead of Scheduled IDMC Charter Meeting –
— IDMC 将在预定的 IDMC 章程会议之前再次召开会议 —
– Next Efficacy and Safety Assessment of All REGAL Patients (n=127) in June 2024 –
— 2024年6月对所有REGAL患者（n=127）进行下一次疗效和安全性评估—
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。